Mutations in TP53, KRAS, LKB1, NF1 and RBM10 are enriched in transversion-high tumours, whilst mutations in EGFR, RB1 and PIK3CA and in-frame insertions in the receptor tyrosine kinases EGFR and ERBB2 are enriched in transversion-low tumours [75]. Here, ERBB2 is linked to neoplasm.